PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.84%
Positive revenue growth while ADI is negative. John Neff might see a notable competitive edge here.
16.44%
Positive gross profit growth while ADI is negative. John Neff would see a clear operational edge over the competitor.
26.41%
EBIT growth above 1.5x ADI's 0.50%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
13.75%
Operating income growth above 1.5x ADI's 0.50%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
0.48%
Net income growth under 50% of ADI's 3.24%. Michael Burry would suspect the firm is falling well behind a key competitor.
2.63%
EPS growth at 75-90% of ADI's 3.13%. Bill Ackman would push for improved profitability or share repurchases to catch up.
No Data
No Data available this quarter, please select a different quarter.
-0.55%
Share reduction while ADI is at 0.08%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.36%
Reduced diluted shares while ADI is at 0.13%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-99.94%
Dividend reduction while ADI stands at 66.25%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
83.07%
OCF growth above 1.5x ADI's 2.92%. David Dodd would confirm a clear edge in underlying cash generation.
86.67%
FCF growth above 1.5x ADI's 5.10%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-2.77%
Negative 10Y revenue/share CAGR while ADI stands at 35.73%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
20.39%
Positive 5Y CAGR while ADI is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
68.07%
3Y revenue/share CAGR above 1.5x ADI's 28.66%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
175.37%
10Y OCF/share CAGR at 75-90% of ADI's 227.51%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
228.76%
5Y OCF/share CAGR above 1.5x ADI's 47.41%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
182.00%
3Y OCF/share CAGR at 50-75% of ADI's 293.13%. Martin Whitman would suspect weaker recent execution or product competitiveness.
102.53%
Net income/share CAGR at 75-90% of ADI's 119.13%. Bill Ackman would press for strategic moves to boost long-term earnings.
-1.52%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
253.22%
3Y net income/share CAGR similar to ADI's 280.31%. Walter Schloss would attribute it to shared growth factors or demand patterns.
186.13%
10Y equity/share CAGR at 50-75% of ADI's 255.23%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
1.13%
Below 50% of ADI's 78.25%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
12.65%
Below 50% of ADI's 27.45%. Michael Burry suspects a serious short-term disadvantage in building book value.
-99.93%
Cut dividends over 10 years while ADI stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-99.92%
Negative 5Y dividend/share CAGR while ADI stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-99.93%
Negative near-term dividend growth while ADI invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
0.68%
Our AR growth while ADI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-3.66%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
3.44%
Asset growth 1.25-1.5x ADI's 2.32%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
4.15%
1.25-1.5x ADI's 3.11%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-0.83%
We’re deleveraging while ADI stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
6.90%
We increase R&D while ADI cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
20.35%
We expand SG&A while ADI cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.